Početna › Multipli mijelom › Georgia › Atlanta
Kliničke studije za Multipli mijelom u gradu Atlanta, GA
Jedna studija za Multipli mijelom traži sudionike na lokaciji u gradu Atlanta ili blizu njega. Otvorite je da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
U tijeku regrutacijaFaza 3
- Research Site, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Emory University Winship Cancer Center, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
- Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
U tijeku regrutacijaFaza 1
- Research Site, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
U tijeku regrutacijaFaza 1
- Winship Cancer Institute Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 3
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- Emory University Winship Cancer Institute, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
U tijeku regrutacijaFaza 3
- Emory University - Winship Cancer Institute, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
U tijeku regrutacijaFaza 4
- Emory University, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Emory University Hospital, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
U tijeku regrutacijaFaza 2/3
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
U tijeku regrutacijaFaza 2
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Winship Cancer Institute of Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
U tijeku regrutacijaOpažajna studija
- Emory University, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
U tijeku regrutacijaFaza 3
- Winship Cancer Institute, Emory University, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
U tijeku regrutacijaFaza 3
- Emory University Hospital Midtown, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
U tijeku regrutacijaFaza 2
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Emory University Hospital, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Research Site, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Research Site, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- The Winship Cancer Institute of Emory University, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
U tijeku regrutacijaFaza 1/2
- Research Site, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
U tijeku regrutacijaFaza 3
- Research Site, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
U tijeku regrutacijaFaza 1
- Winship Cancer Institute, Emory University, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- Winship Cancer Institute, Emory University, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
U tijeku regrutacijaFaza 4
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
U tijeku regrutacijaFaza 1/2
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Northside Hospital, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
U tijeku regrutacijaFaza 1
- Winship Cancer Institute of Emory University, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
U tijeku regrutacijaFaza 1/2
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
U tijeku regrutacijaFaza 1
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
U tijeku regrutacija
- Emory University Hospital/Winship Cancer Institute, Atlanta
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
U tijeku regrutacijaFaza 3
- Emory University Hospital, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Emory Winchip Cancer Center, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
U tijeku regrutacijaFaza 3
- GSK Investigational Site, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
U tijeku regrutacijaFaza 2
- Caitlin Guzowski, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- Emory University Hospital, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
U tijeku regrutacijaFaza 1
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
U tijeku regrutacijaFaza 1/2
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
U tijeku regrutacijaFaza 1
- Northside Hospital, Atlanta
Studije za Multipli mijelom u drugim gradovima
- New York City, NY60 studija
- Boston, MA42 studija
- Houston, TX38 studija
- Durham, NC37 studija
- Nashville, TN32 studija
- Denver, CO27 studija
- Rochester, MN24 studija
- St. Louis, MO24 studija
- Columbus, OH24 studija
- Baldwin Park, CA23 studija
- Chicago, IL22 studija
- Seattle, WA22 studija
Ostale studije u gradu Atlanta
- Rak (sve vrste)49 studija
- Nemikrocelularni karcinom pluća47 studija
- Rak dojke41 studija
- Rak prostate33 studija
- Akutna mijeloična leukemija30 studija
- Rak jajnika29 studija
- Rak pluća29 studija
- Kolorektalni rak29 studija
- Metastatski karcinom28 studija
- Srčano zatajenje25 studija
- Veliki depresivni poremećaj25 studija
- Pločastostanični karcinom glave i vrata24 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.